Investor Presentaiton

HER3-DXD HERTHENA-Lung01 study Planned regulatory submission in US in FY2023 H2 Clinical studies of HER3-DXd in EGFR mutated NSCLC Advanced/Metastatic 1L 2L 3L HERTHENA- Lung02 Ph3 (HER3-DXd mono vs chemo) HERTHENA- Lung01 registrational Ph2 ■ Announced the TLR outline in FY2022 Q4 earnings call • · Daiichi-Sankyo 5.6 mg/kg dose showed durable responses in patients with metastatic or locally advanced EGFR mutated NSCLC previously treated with an EGFR TKI and PBC No new safety concerns identified ■ Clinical data to be presented at WCLC in Sep 2023 ■ Other ongoing EGFR mutated NSCLC studies: HERTHENA-Lung02 study (2L, Ph3) • Osimertinib combination Ph1b study Osimertinib combination Ph1b NSCLC: non-small cell lung cancer, PBC: platinum-based chemotherapy, TKI: tyrosine kinase inhibitor, WCLC: World Conference of Lung Cancer 23

View entire presentation